Drug development for neglected diseases | TATuP - Zeitschrift für Technikfolgenabschätzung in Theorie und Praxis
Drug development for neglected diseases
Field test for various open innovation initiatives
Katrin Gerlinger Büro für Technikfolgen-Abschätzung beim Deutschen Bundestag (TAB), Karlsruher Institut für Technologie (KIT) (DE) http://orcid.org/0000-0001-9454-2625 gerlinger@tab-beim-bundestag.de
neglected diseases, research and development, market failure, open innovation	
There is a lack of sufficient research and development regarding diseases almost exclusively affection poor countries. One reason is seen in the financially weak demand, which can not sufficiently stimulate the complex commercialized product development. In recent years, national and international measures have been discussed and partly been implemented to attenuate the systemic problem of the patent-based innovation process, at least for poverty-related diseases. Some Stakeholders are testing how the idea of open source software development – the collaboration of volunteers generate products that are not owned by a company – can be transferred to drug development. They open different elements of the pharmacological innovation process for sharing and further drug development. Partly they call this Open Innovation. The article presents relevant initiatives.
Gerlinger K. Drug development for neglected diseases: Field test for various open innovation initiatives. TATuP [Internet]. 2017 Aug. 15 [cited 2021 Dec. 9];26(1-2):37-42. Available from: https://www.tatup.de/index.php/tatup/article/view/24